Chronicle Journal: Finance

Mylan Files Annual Report on Form 10-K for Year Ended Dec. 31, 2014

POTTERS BAR, England and PITTSBURGH, March 2, 2015 /PRNewswire/ -- Mylan N.V. (Nasdaq: MYL) and Mylan Inc. today announced that Mylan Inc. filed its Annual Report on Form 10-K for the year ended December 31, 2014 with the U.S. Securities and Exchange Commission on March 2, 2015. The Annual Report is available through the Investors section of the company's website at www.mylan.com/investors. In addition, the company's shareholders may receive a hard copy of the Annual Report, free of charge, upon request by contacting Mylan Investor Relations at 724.514.1813 or investor.relations@mylan.com.

Mylan

Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of around 1,400 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in about 145 countries and territories. Our workforce of approximately 30,000 people is dedicated to creating better health for a better world, one person at a time. Learn more at mylan.com.

Logo - http://photos.prnewswire.com/prnh/20140423/77793

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mylan-files-annual-report-on-form-10-k-for-year-ended-dec-31-2014-300043972.html

SOURCE Mylan N.V.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.